Valencia, CA-based radiopharmaceutical company Nusano has received $115 million in a funding round for initial product launches of medical isotopes lutetium-177 (Lu-177) and actinium-225 (Ac-225).
The company is building a new production facility in Utah’s Salt Lake Valley slated to open this year and capable of generating more than 25 radioisotopes applicable to medical and industrial uses, the company said. The facility is driven by proprietary ion source technology that accelerates heavy particles (alphas and deuterons) to generate high-volume, high-quality (cGMP-grade) radioisotopes using ecofriendly methods, Nusano added.
The funding round was led by the Wasatch Group, with additional participation by S32. Previous investors in Nusano include Verily and the American Cancer Society’s BrightEdge, the company said.
